(2S,3S,4S,5R,6S)-6-{[(1S,5R,13R,14R,17S)-4-(cyclopropylmethyl)-14,17-dihydroxy(13,14,15,15-2H4)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-10-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

• ChemBase编号: 174945
• 分子式: C26H33NO10
• 平均质量: 519.54092
• 单一同位素质量: 519.21044626
• SMILES: c1(c2c3c(cc1)C[C@@H]1[C@]4([C@@]3([C@H]([C@@H](CC4)O)O2)CCN1CC1CC1)O)O[C@@H]1O[C@H]([C@H]([C@@H]([C@@H]1O)O)O)C(=O)O
• Canonical SMILES: O[C@@H]1[C@H](O)[C@@H](O[C@H]([C@H]1O)C(=O)O)Oc1ccc2c3c1O[C@@H]1[C@@]43CCN([C@H](C2)[C@]4(O)CC[C@H]1O)CC1CC1
• InChI: InChI=1S/C26H33NO10/c28-13-5-6-26(34)15-9-12-3-4-14(35-24-19(31)17(29)18(30)21(37-24)23(32)33)20-16(12)25(26,22(13)36-20)7-8-27(15)10-11-1-2-11/h3-4,11,13,15,17-19,21-22,24,28-31,34H,1-2,5-10H2,(H,32,33)/t13-,15-,17+,18+,19-,21+,22?,24-,25+,26-/m1/s1
• InChIKey: MZOUDXNTQKTCTC-JNWORINHSA-N

名称和登记号

名称

• IUPAC标准名: (2S,3S,4S,5R,6S)-6-{[(1S,5R,13R,14R,17S)-4-(cyclopropylmethyl)-14,17-dihydroxy(13,14,15,15-^2H₄)-12-oxa-4-azapentacyclo[9.6.1.0^1,^1^3.0^5,^1^7.0^7,^1^8]octadeca-7(18),8,10-trien-10-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid
• IUPAC传统名: (2S,3S,4S,5R,6S)-6-{[(1S,5R,13R,14R,17S)-4-(cyclopropylmethyl)-14,17-dihydroxy(13,14,15,15-^2H₄)-12-oxa-4-azapentacyclo[9.6.1.0^1,^1^3.0^5,^1^7.0^7,^1^8]octadeca-7(18),8,10-trien-10-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid
• 别名: (5α,6β)-17-(Cyclopropylmethyl)-4,5-epoxy-6,14-dihydroxy-morphinan-3-yl-d4 β-D-Glucopyranosiduronic Acid; 6β-Naltrexol-d4 3-O-β-D-Glucuronide

登记号

• PubChem SID: 164230855
• PubChem CID: 71750921

理论计算性质

• Acid pKa: 2.6639822
• 质子受体: 11
• 质子供体: 6
• LogD (pH = 5.5): -3.420972
• LogD (pH = 7.4): -3.4226851
• Log P: -3.4206746
• 摩尔折射率: 124.4107 cm^3
• 极化性: 50.034843 Å^3
• 极化表面积: 169.38 Å^2
• 可自由旋转的化学键: 5
• 里宾斯基五规则: false

详细说明

Toronto Research Chemicals - N285712

A labelled metabolite of 6β-Naltrexol (N285700). Narcotic antagonist.

参考文献

• Portoghese, P. et al,: J. Med. Chem., 37, 579 (1994)
• Ohkawa, S., et al.: J. Med. Chem., 41, 4177 (1994)